Sung-Ho Park

Title: The Innovative Contributions of Sung-Ho Park

Introduction

Sung-Ho Park is a notable inventor based in Gwangmyeong, South Korea. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target specific diseases. With a total of 3 patents to his name, Park's work is recognized for its potential impact on cancer treatment and other kinase-mediated conditions.

Latest Patents

One of Park's latest patents involves pyridopyrimidinone derivatives for use as AXL inhibitors. This patent discloses pharmaceutical compositions containing these derivatives aimed at treating diseases mediated by AXL, such as cancer and metastasis. The patent also outlines methods for treating AXL-mediated diseases by administering a therapeutically effective amount of the pyridopyrimidinone derivative. Another significant patent focuses on substituted pyrimidine compounds and their use as SYK inhibitors. This patent details compounds of Formula (I) and methods for inhibiting kinases, including spleen tyrosine kinases. It also describes methods for treating kinase-mediated diseases by administering a therapeutically effective amount of the compound.

Career Highlights

Throughout his career, Sung-Ho Park has worked with various companies, including Oscotec Inc. and Genosco. His experience in these organizations has contributed to his expertise in pharmaceutical innovations and the development of therapeutic compounds.

Collaborations

Park has collaborated with notable coworkers, including Dong-Sik Jung and Jung-Ho Kim. These partnerships have likely enhanced his research and development efforts in the pharmaceutical field.

Conclusion

Sung-Ho Park's innovative work in developing AXL and SYK inhibitors showcases his commitment to advancing medical science. His contributions have the potential to significantly impact the treatment of various diseases, particularly cancer.